



---

# STUDY OF CANDIDA ALBICANS AND ASPERGILLUS FUMIGATUS AMONG EGYPTIAN POPULATION WITH ALLERGIC BRONCHIAL ASTHMA

---

Radwa Hassan Abou El Fotoh



[DATE]  
[COMPANY NAME]  
[Company address]

# **Study of *Candida Albicans* & *Aspergillus fumigatus* sensitization among Egyptian patients with allergic bronchial asthma**

**Thesis**

*Submitted for Partial Fulfillment of Master Degree in Internal  
Medicine*

**By**

**Radwa Hassan Abou El Fotoh**

*M.B.B. Ch - Ain Shams University*

***Supervised By***

**Prof. Dr. Fawzia Hassan Abou Ali**

*Professor of Internal Medicine and Clinical Immunology Faculty of Medicine – Ain  
Shams University*

**Dr. Osama Mohamed Abdel Latif**

*Lecturer of Internal Medicine and Clinical Immunology Faculty of Medicine - Ain  
Shams University*

**Dr. Hoda Mohammed El Sayed**

Lecturer of Internal Medicine and Clinical Immunology  
Faculty of Medicine- Ain Shams University

**Faculty of Medicine  
Ain shams University  
2016**

# دراسة التحسس لفطر الكنديدا البيضاء والأسبرجلس فيوميجاتس بين المرضى المصريين الذين يعانون من الربو الشعبي التحسسي

رسالة توطئة

للحصول على درجة الماجستير

في الباطنة العامة

مقدمة من

الطبيبة / رضوى حسن أبو الفتوح

بكالوريوس الطب والجراحة

تحت إشراف

**الأستاذة الدكتورة/ فوزية حسن أبو على**

أستاذ الباطنة العامة والحساسية والمناعة

كلية الطب - جامعة عين شمس

**الدكتور/ أسامة محمد عبد اللطيف**

مدرس الباطنة العامة والحساسية والمناعة

كلية الطب - جامعة عين شمس

**الدكتور/ هدى محمد السيد**

مدرس الباطنة العامة والحساسية والمناعة

كلية الطب - جامعة عين شمس

كلية الطب

جامعة عين شمس

2016

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

# قالوا

لسببانك لا نعلم لنا  
إلا ما علمتنا إنك أنت  
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢



## **Acknowledgement**

*First, the foremost word to be written is “thanks my Lord for your help to finish this work”.*

*Second, from among the numerous great people whose involvement in this study was invaluable, I would like to distinguish the following individuals:*

*My sincere gratitude is due to **Prof. Dr. Fawzia Hassan Abou Ali**, Profosser of Internal Medicine, Ain Shams University, for her supervision, expert guidance, valuable help and advice throughout. Her wide knowledge and experience were very helpful to me.*

*I feel also extremely grateful to **Dr. Osama Mohammed Abdel Latif**, Lecturer of Internal Medicine, Ain Shams University, for his supervision, everlasting support and encouragement throughout this study.*

*I am indebted to **Dr. Hoda Mohammed El Sayed**, Lecturer of Internal Medicine, Ain Shams University, for her kind treatment, generosity and extraordinary effort in supervising and instructing me.*

*At last, I would like to thank my family who stood beside me to finish this work (my husband, my mother and all my family).*

# *List of Contents*

|                                                               | Page No. | Title |
|---------------------------------------------------------------|----------|-------|
| <b>Introduction</b> .....                                     | 1        |       |
| <b>Aim of the Work</b> .....                                  | 4        |       |
| <b>Review of Literature</b>                                   |          |       |
| • Chapter 1: Bronchial Asthma.....                            | 5        |       |
| • Chapter 2: Fungal sensitization in bronchial<br>asthma..... | 60       |       |
| <b>Subjects and methods</b> .....                             | 94       |       |
| <b>Results</b> .....                                          | 108      |       |
| <b>Discussion</b> .....                                       | 120      |       |
| <b>Conclusion and Recommendations</b> .....                   | 131      |       |
| <b>Summary</b> .....                                          | 133      |       |
| <b>References</b> .....                                       | 136      |       |
| <b>Arabic Summary</b> .....                                   | 197      |       |



## *List of Tables*

| <b>Table No</b>   | <b>Title</b>                                                                                                                                                               | <b>Page No</b> |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| <b>Table (1)</b>  | Diagnostic criteria for asthma in adults, adolescents, and children 6–11 years                                                                                             | 25             |
| <b>Table (2)</b>  | Differential diagnosis of asthma in adults, adolescents and children 6–11 years                                                                                            | 30             |
| <b>Table (3)</b>  | Treating modifiable risk factors to reduce exacerbations                                                                                                                   | 50             |
| <b>Table (4)</b>  | Non-pharmacological intervention for asthma management                                                                                                                     | 52             |
| <b>Table (5)</b>  | Investigation and management of severe asthma                                                                                                                              | 59             |
| <b>Table (6)</b>  | Taxonomy of selected allergenic fungi                                                                                                                                      | 61             |
| <b>Table (7)</b>  | Major allergens and their biologic activity for 4 major genera of allergenic fungi                                                                                         | 64             |
| <b>Table (8)</b>  | The differences between fungal sensitization, severe asthma with fungal sensitization and allergic bronchopulmonary mycosis                                                | 80             |
| <b>Table (9)</b>  | Performance characteristics of skin prick test, intradermal skin test when skin pricktest result is negative and in vitro tests for specific IgE to <i>Alternaria</i>      | 81             |
| <b>Table (10)</b> | Diagnostic criteria for Allergic Bronchopulmonary Aspergillosis                                                                                                            | 82             |
| <b>Table (11)</b> | American Thoracic Society Grades for severity of a pulmonary function test abnormality                                                                                     | 98             |
| <b>Table (12)</b> | Characteristics of the whole study cohort                                                                                                                                  | 108            |
| <b>Table (13)</b> | Results of the SPT, BPT, and ultimate classification of the whole study cohort                                                                                             | 111            |
| <b>Table (14)</b> | Characteristics of patients who were classified as non-allergic to <i>Candida</i> and/or <i>Aspergillus</i> and those allergic to <i>Candida</i> and/or <i>Aspergillus</i> | 113            |



---

**✍ List of Tables**

---

|                   |                                                                                                                                                                                                                    |     |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| <b>Table (15)</b> | Result of the laboratory and spirometric work-up in patients who were classified as non-allergic to <i>Candida</i> and/or <i>Aspergillus</i> and those allergic to <i>Candida</i> and/or <i>Aspergillus</i> by SPT | 114 |
| <b>Table (16)</b> | Prevalence of allergy to other allergens in patients who were classified as non-allergic to <i>Candida</i> and/or <i>Aspergillus</i> and those allergic to <i>Candida</i> and/or <i>Aspergillus</i> by SPT         | 116 |
| <b>Table (17)</b> | Number of sensitizers in patients who were classified as non-allergic to <i>Candida</i> or <i>Aspergillus</i> and those allergic to <i>Candida</i> and/or <i>Aspergillus</i> by SPT                                | 117 |
| <b>Table (18)</b> | Positive predictive value of <i>Candida</i> BPT                                                                                                                                                                    | 119 |
| <b>Table (19)</b> | Positive predictive value of <i>Aspergillus</i> BPT                                                                                                                                                                | 119 |





## *List of Figures*

| <b>Figure: No</b> | <b>Title</b>                                                                                                                                                           | <b>Page No</b> |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| <b>Figure (1)</b> | Worldwide prevalence of clinical asthma                                                                                                                                | 8              |
| <b>Figure (2)</b> | Th2 and Th17 allergen responses in the asthmatic airway.                                                                                                               | 23             |
| <b>Figure (3)</b> | Geographical distribution of fungal allergy.                                                                                                                           | 68             |
| <b>Figure (4)</b> | Natural history of asthma in relation to fungal sensitization                                                                                                          | 76             |
| <b>Figure (5)</b> | Microspiro HI-601                                                                                                                                                      | 96             |
| <b>Figure (6)</b> | Number of sensitizers by SPT in the whole study cohort.                                                                                                                | 112            |
| <b>Figure (7)</b> | Total serum IgE level in patients who were classified as non-allergic to Candida or Aspergillus and those allergic to Candida, Aspergillus, or both agents by SPT.     | 115            |
| <b>Figure (8)</b> | The number of sensitizers in patients who were classified as non-allergic to Candida or Aspergillus and those allergic to Candida, Aspergillus, or both agents by SPT. | 118            |



## *List of Abbreviations*

|                |                                                                     |
|----------------|---------------------------------------------------------------------|
| <b>AAFS</b>    | Asthma associated with fungal sensitization                         |
| <b>AAS</b>     | Allergic Aspergillus Sinusitis                                      |
| <b>ABPA</b>    | Allergic BronchoPulmonary Aspergillosis                             |
| <b>ABPA-CB</b> | Allergic bronchopulmonary aspergillosis with central bronchiectasis |
| <b>ABPA-S</b>  | Seropositive allergic bronchopulmonary aspergillosis                |
| <b>ABPM</b>    | Allergic bronchopulmonary mycosis                                   |
| <b>ACE</b>     | Angiotensin converting enzyme                                       |
| <b>ACOS</b>    | Asthma–COPD overlap syndrome                                        |
| <b>ACQ</b>     | Asthma Control Questionnaire                                        |
| <b>ACT</b>     | Asthma control test                                                 |
| <b>AERD</b>    | Aspirin-exacerbated respiratory disease                             |
| <b>AH</b>      | Aspergillus hypersensitivity                                        |
| <b>ASMCs</b>   | Airway smooth muscle cells                                          |
| <b>BD</b>      | Bronchodilator                                                      |
| <b>BPT</b>     | Bronchial provocation test                                          |
| <b>CD</b>      | Cluster of differentiation                                          |
| <b>CF</b>      | Cystic fibrosis                                                     |
| <b>COPD</b>    | Chronic obstructive pulmonary disease                               |
| <b>COX</b>     | Cyclooxygenase                                                      |
| <b>CP3A4</b>   | Cytochrome P3A4                                                     |
| <b>DCs</b>     | Dendritic cells                                                     |
| <b>DNA</b>     | Deoxyribonucleic acid                                               |
| <b>ECRHS</b>   | European Community Respiratory Health Survey                        |
| <b>EIB</b>     | Exercise induced bronchoconstriction                                |
| <b>ELF</b>     | Extra-cellular lung fluid                                           |
| <b>ELISA</b>   | Enzyme-linked immunosorbent assay                                   |
| <b>FeNO</b>    | Fractional exhaled nitric oxide                                     |
| <b>FEV1</b>    | Forced Expiratory Volume in first second                            |
| <b>FVC</b>     | Forced vital capacity                                               |
| <b>GINA</b>    | Global initiative for asthma                                        |

## Introduction

|                               |                                                                    |
|-------------------------------|--------------------------------------------------------------------|
| <b>GM-CSF</b>                 | Granulocyte-macrophage colony-stimulating factor                   |
| <b>GOLD</b>                   | Global Strategy for Management of Chronic Obstructive Lung Disease |
| <b>GR-<math>\beta</math></b>  | Glucocorticoid receptor beta                                       |
| <b>GWAS</b>                   | genome-wide association study                                      |
| <b>HCV</b>                    | Hepatitis C virus                                                  |
| <b>HDM</b>                    | House dust mite                                                    |
| <b>HLA</b>                    | The human leukocyte antigen                                        |
| <b>ICS</b>                    | Inhaled corticosteroids                                            |
| <b>IgE</b>                    | Immunoglobulin E                                                   |
| <b>IL</b>                     | Interleukin                                                        |
| <b>IL-1<math>\beta</math></b> | Interleukin 1 beta                                                 |
| <b>INF</b>                    | Interferon                                                         |
| <b>KIU/l</b>                  | Kilo international unit per litre                                  |
| <b>LABA</b>                   | Long-acting beta2-agonist                                          |
| <b>LR</b>                     | Likelihood ratio                                                   |
| <b>LTRA</b>                   | Leukotriene receptor antagonists                                   |
| <b>MCP-1</b>                  | Macrophage chemoattractant protein-1                               |
| <b>MHC</b>                    | Major histocompatibility complex                                   |
| <b>MMP-9</b>                  | Neutrophils release matrix metalloproteinase 9                     |
| <b>MnSOD</b>                  | Manganese superoxide dismutase                                     |
| <b>NSAIDs</b>                 | Non-steroidal anti-inflammatory drugs                              |
| <b>OCS</b>                    | Oral Corticosteroids                                               |
| <b>PAF</b>                    | Platelet-activating factor                                         |
| <b>PEF</b>                    | Peak expiratory flow                                               |
| <b>PFT</b>                    | Pulmonary function test                                            |
| <b>PPV</b>                    | Positive predictive value                                          |
| <b>RANTES</b>                 | Regulated on Activation, Normal T Cell Expressed and Secreted      |
| <b>RAST</b>                   | Radioallergosorbent test                                           |
| <b>RCP</b>                    | Royal College of Physicians                                        |
| <b>SABA</b>                   | Short-acting beta2-agonist                                         |
| <b>SAFS</b>                   | Severe asthma with fungal sensitization                            |
| <b>SARP</b>                   | Severe Asthma Research Program                                     |

---

## Introduction

---

|                                |                                        |
|--------------------------------|----------------------------------------|
| <b>SCF</b>                     | Stem cell factor                       |
| <b>SCIT or</b>                 | Sub-cutaneous immunotherapy            |
| <b>sIgE</b>                    | specific immunoglobulin E              |
| <b>SLIT</b>                    | Sub-lingual immunotherapy              |
| <b>SNPs</b>                    | single nucleotide polymorphisms        |
| <b>SPT</b>                     | Skin Prick Test                        |
| <b>TH0</b>                     | Naïve T-helper cell (undifferentiated) |
| <b>Th2</b>                     | T-helper type 2                        |
| <b>TLR</b>                     | Toll-like receptor                     |
| <b>TMB</b>                     | Tetramethylbenzidine                   |
| <b>TNF-<math>\alpha</math></b> | Tumor necrosis factor alpha            |
| <b>TSLP</b>                    | Thymic stromal lymphopoietin           |
| <b>TSLPR</b>                   | Thymic stromal lymphopoietin receptor  |
| <b>UK</b>                      | United kingdom                         |
| <b>USA</b>                     | United states of America               |
| <b>VOCs</b>                    | Volatile organic compounds             |
| <b>WHO</b>                     | World health organization              |

## Introduction

The word asthma is a derivation from the ancient Greek, *aazein*, meaning “gasping” or “panting”. **(Marketos et al, 1982)** Asthma is a common and potentially serious chronic disease that imposes a substantial burden on patients, their families and the community. It causes respiratory symptoms, limitation of activity, and flare-ups (attacks) that sometimes require urgent healthcare and may be fatal. Fortunately, asthma can be effectively treated, and most patients can achieve good control of their asthma. **(Reddel et al, 2015)**

Sensitization to fungi is an important factor in patients with allergic respiratory tract diseases, playing a major role in the development, persistence, and severity of lower airway disease, particularly asthma. Direct associations between increased fungal exposure and loss of asthma control are numerous, but only recently have direct causal associations with the development of asthma become apparent. **(Denning et al, 2006)**

Various studies report that 12% to 42% of atopic patients are mould sensitive. **(Bartra et al, 2009; Hedayati et al, 2009; Almogren et al, 2009)** It is reported that Sixty-six percent of mould sensitized patients were sensitive to one or more fungi based on SPT and/or specific serum IgE results. Positivity to SPT and/or specific serum IgE was 45%

---

## ✍ Introduction

---

for *A. fumigatus* & 36% for *C. albicans*. (**O'Driscoll *et al*, 2009**)

*Aspergillus*, a genus of spore-forming fungi found worldwide, is linked to asthma in more ways than one. This generally develops in atopic subjects and is sustained by continuous inhalation of *Aspergillus* antigens, triggering asthma. The clinical spectrum of *Aspergillus*-associated hypersensitivity respiratory disorders includes *Aspergillus* induced asthma, allergic bronchopulmonary aspergillosis (ABPA) and allergic *Aspergillus* sinusitis (AAS). (**Shah, 1998**)

The reported frequency of *Aspergillus* sensitization in patients with asthma has varied from 16-38% in different parts of the world. (**Longbottom and Pepys, 1964; Hendrick *et al*, 1975; Schwartz *et al*, 1978; Maurya *et al*, 2005**)

In Delhi, they found that (28.5%) of patients with asthma had a positive skin test to *Aspergillus* antigens. In Cleveland and London, they found that 28% and 23% of patients respectively had immediate skin reactivity to *Aspergillus* antigens. (**Maurya *et al*, 2005; Schwartz *et al*, 1978**)

While the role of several moulds as aero-allergens has been studied, the significance of the yeast *Candida albicans* in allergic diseases is still unclear. Studies of *Candida* as a potential allergen are rather few. Earlier studies found that

---

## ✍ Introduction

---

sensitization to this yeast is associated with chronic asthma and rhinitis both in children and adults (**Asero and Bottazzi, 2004; Shah, 2004**)

In a study of fungal allergy Positive SPT with mould allergens were found among 10.8% farmers and 6.8% bakers with occupational allergy. The fungi allergens giving positive SPT results most frequently were *Candida albicans*, *Levures mélanges*, *Aspergillus mix.* and *Charbons cerealiers* in both groups. (**Wiszniewska et al, 2013**)